Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +217.1%
S&P 500 total return (same window) +37.0%
Excess return +180.1%

Annualized: +151.9% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 98.3% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 92.2%
Other/Unmapped 7.8%

Full portfolio 33 positions

05
Type Streak 8Q trend
RLAY Relay Therapeutics, Inc. - Common Stock $224,520,000 13.37% 12,000,000 $55,370,000 Down ×1
ELVN Enliven Therapeutics, Inc. - Common Stock $166,206,250 9.90% 3,275,000 $37,826,250
ALKS Alkermes plc - Ordinary Shares $157,185,000 9.36% 3,000,000 $8,673,000 Down ×1
COGT Cogent Biosciences, Inc. - Common Stock $118,035,000 7.03% 3,050,000 $6,875,611 Up ×2
AMLX Amylyx Pharmaceuticals, Inc. - Common Stock $101,474,000 6.04% 5,650,000 $22,939,000
DFTX Definium Therapeutics, Inc. - Common Shares $94,080,000 5.60% 2,000,000 $56,280,000
SYRE Spyre Therapeutics, Inc. - Common Stock $75,177,661 4.48% 846,786 $-21,282,786 Down ×2
ANRO Alto Neuroscience, Inc. Common Stock $71,865,142 4.28% 2,723,196 $10,647,696
TNGX Tango Therapeutics, Inc. - Common Stock $70,335,000 4.19% 2,250,000
EYPT EyePoint, Inc. - Common Stock $65,780,000 3.92% 4,600,000 $29,365,750 Up ×1
TYRA Tyra Biosciences, Inc. - Common Stock $59,887,500 3.57% 1,875,000 $-34,905,000 Down ×2
GLTO Galecto, Inc. - Common Stock $50,433,390 3.00% 1,939,000 $213,290
CLDX Celldex Therapeutics, Inc. - Common Stock $50,233,500 2.99% 1,350,000 $-35,303,160 Down ×1
PHVS Pharvaris N.V. - Ordinary Shares $49,276,500 2.93% 1,425,000 $-4,934,403 Down ×1
LBRX LB Pharmaceuticals Inc - Common Stock $48,682,500 2.90% 1,500,000 $11,692,500
ASMB Assembly Biosciences, Inc. - Common Stock $38,884,200 2.32% 1,415,000 $11,134,200 Up ×1
EDIT Editas Medicine, Inc. - Common Stock $28,800,360 1.72% 8,889,000 Up ×1
KYMR Kymera Therapeutics, Inc. - Common Stock $28,667,500 1.71% 250,000 $-33,800,000 Down ×1
CATX CUSIP: 46489V302 $21,608,427 1.29% 6,336,782 $-4,815,954
IPSC Century Therapeutics, Inc. - Common Stock $21,304,347 1.27% 8,695,652 $1,652,173
ZURA Zura Bio Limited - Class A Ordinary shares $19,175,000 1.14% 3,250,000 $-162,500
AVTX Avalo Therapeutics, Inc. - Common Stock $18,818,535 1.12% 1,018,319 $11,607,345 Up ×1
IFRX InflaRx N.V. - Common Stock $16,352,000 0.97% 7,300,000 Up ×1
ANTX AN2 Therapeutics, Inc. - Common Stock $14,199,011 0.85% 2,933,680 $6,217,713 Up ×1
NUVL Nuvalent, Inc. - Class A Common Stock $12,350,000 0.74% 100,000 $-73,052,320 Down ×1
SABS SAB Biotherapeutics, Inc. - Common Stock $11,193,000 0.67% 2,870,000 $-5,664,745 Down ×1
IKT Inhibikase Therapeutics, Inc. - Common Stock $10,956,901 0.65% 5,397,488 $1,889,121
RLMD Relmada Therapeutics, Inc. - Common Stock $9,861,000 0.59% 1,425,000 $5,449,049 Up ×1
PEPG PepGen Inc. - Common Stock $8,055,000 0.48% 4,475,000 $134,250
Unknown issuer (CUSIP: G75226103) $5,350,000 0.32% 500,000 Up ×1
HLXC Helix Acquisition Corp. III - Class A Ordinary Shares $5,320,000 0.32% 500,000 $240,000
LONA LeonaBio, Inc. - Common Stock $4,267,818 0.25% 464,398 $-506,193
VTGN Vistagen Therapeutics, Inc. - Common Stock $630,228 0.04% 2,788,620

Biggest new bets

09

New positions opened this quarter, largest first.

SecurityValueShares% of portfolio
TNGX $70,335,000 2,250,000 4.19%
EDIT $28,800,360 8,889,000 1.72%
IFRX $16,352,000 7,300,000 0.97%
Unknown issuer (CUSIP: G75226103) $5,350,000 500,000 0.32%
VTGN $630,228 2,788,620 0.04%

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
DFTX Price move only +0 +$56.3M
RLAY Trimmed -5.0M +$55.4M
ELVN Price move only +0 +$37.8M
CLDX Trimmed -1.3M -$35.3M
TYRA Trimmed -600K -$34.9M
KYMR Trimmed -500K -$33.8M
EYPT Bought more +1.8M +$29.4M
AMLX Price move only +0 +$22.9M
SYRE Trimmed -1.1M -$21.3M
LBRX Price move only +0 +$11.7M

1 position hidden — reported move looks larger than the position itself (data completeness check)

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
MRUS Dec. 31, 2025 3,525,000 $331,878,750 No longer tracked
AGIO Dec. 31, 2025 2,338,287 $93,858,840 16.8%
VRDN Dec. 31, 2025 3,200,000 $69,056,000 -37.7%
PCVX June 30, 2025 1,650,000 $62,304,000 73.7%
TERN March 31, 2026 1,475,000 $59,590,000 No longer tracked
CDTX Dec. 31, 2025 585,000 $56,019,600 No longer tracked
ORKA March 31, 2026 1,753,054 $53,135,067 72.3%
ERAS June 30, 2026 3,175,000 $51,371,500 -19.5%
SRRK Sept. 30, 2025 1,450,000 $51,359,000 25.7%
XENE June 30, 2026 825,000 $47,973,750 -37.0%
PTGX March 31, 2026 450,000 $39,303,000 32.9%
NRIX June 30, 2026 2,275,000 $35,262,500 -5.2%
CRVS June 30, 2026 2,258,735 $33,045,293 -27.0%
CTMX March 31, 2026 7,692,300 $32,769,198 -45.5%
MNMD March 31, 2026 2,000,000 $26,780,000 No longer tracked
CNTA March 31, 2026 1,000,000 $25,010,000 No longer tracked
SLNO June 30, 2026 652,432 $21,843,423 No longer tracked
OCUL June 30, 2026 2,575,000 $21,810,250 -29.1%
SLDB June 30, 2025 5,825,000 $21,552,500 40.7%
VERA Sept. 30, 2025 800,000 $18,848,000 4.7%
CRDF June 30, 2025 5,384,616 $16,907,694 -64.4%
REPL March 31, 2026 1,425,000 $13,851,000 70.8%
TNGX Dec. 31, 2025 1,500,000 $12,600,000 162.3%
PALI June 30, 2026 7,181,062 $12,566,859 -31.1%
APGE Dec. 31, 2025 290,000 $11,521,700 No longer tracked
ORIC June 30, 2025 2,000,000 $11,160,000 20.2%
KPTI June 30, 2026 1,950,000 $10,861,500 -91.8%
ENTA Dec. 31, 2025 800,000 $9,576,000 -17.8%
CTNM March 31, 2026 816,326 $9,330,606 0.5%
RAPT March 31, 2026 250,000 $8,467,500 No longer tracked
PCSC Dec. 31, 2025 750,000 $7,920,000 No longer tracked
CELC June 30, 2025 695,650 $7,033,022 440.1%
NGNE Sept. 30, 2025 427,866 $6,396,597 48.0%
VTGN Dec. 31, 2025 1,575,000 $5,591,250 -57.4%
CBIO Dec. 31, 2025 450,829 $5,360,357 20.7%
DRUG March 31, 2026 18,851 $1,471,132 -30.5%